Literature DB >> 10587983

Improving treatment for persons with schizophrenia.

A F Lehman1.   

Abstract

The time has come for the development of standards to ensure quality and cost-effective care for the treatment of persons with schizophrenia. Advances in understanding the efficacy of treatments for schizophrenia, the promise of new treatment advances derived from a rapidly evolving neuroscience, pressures to contain health care costs while maintaining or increasing quality, and the growth of advocacy on behalf of persons with schizophrenia are driving this need. The evidence for the efficacy of pharmacotherapies, psychological interventions, family interventions, vocational rehabilitation, and case management and assertive community treatment is substantial, yet many patients do not receive treatments consistent with this evidence. Service systems must do much more to ensure that efficacious treatments are available, that both effectiveness and costs are considered in the allocation of resources, and that evaluative systems are in place to promote on-going quality improvement to provide the best care.

Entities:  

Mesh:

Year:  1999        PMID: 10587983     DOI: 10.1023/a:1022082031007

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  18 in total

Review 1.  Risperidone: efficacy and safety.

Authors:  D Umbricht; J M Kane
Journal:  Schizophr Bull       Date:  1995       Impact factor: 9.306

Review 2.  Family interventions for schizophrenia.

Authors:  L B Dixon; A F Lehman
Journal:  Schizophr Bull       Date:  1995       Impact factor: 9.306

Review 3.  Clozapine: efficacy and safety.

Authors:  R W Buchanan
Journal:  Schizophr Bull       Date:  1995       Impact factor: 9.306

Review 4.  Conventional antipsychotic medications for schizophrenia.

Authors:  L B Dixon; A F Lehman; J Levine
Journal:  Schizophr Bull       Date:  1995       Impact factor: 9.306

Review 5.  Psychological interventions for schizophrenia.

Authors:  J E Scott; L B Dixon
Journal:  Schizophr Bull       Date:  1995       Impact factor: 9.306

6.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

7.  Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

Authors:  A F Lehman; D M Steinwachs
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

Review 8.  The costs of schizophrenia. Assessing the burden.

Authors:  A Rupp; S J Keith
Journal:  Psychiatr Clin North Am       Date:  1993-06

9.  Risperidone in the treatment of schizophrenia.

Authors:  S R Marder; R C Meibach
Journal:  Am J Psychiatry       Date:  1994-06       Impact factor: 18.112

10.  Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.

Authors:  T F Seeger; P A Seymour; A W Schmidt; S H Zorn; D W Schulz; L A Lebel; S McLean; V Guanowsky; H R Howard; J A Lowe
Journal:  J Pharmacol Exp Ther       Date:  1995-10       Impact factor: 4.030

View more
  1 in total

Review 1.  The efficacy of assertive community treatment to treat substance use.

Authors:  Heather P Fries; Marc I Rosen
Journal:  J Am Psychiatr Nurses Assoc       Date:  2011 Jan-Feb       Impact factor: 2.385

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.